About Jade Biosciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://jadebiosciences.com/
Frequently Asked Questions
What is the 52-week range for JBIO?
The 52-week high is $28 and the 52-week low is $8.16.
What is the P/E ratio for JBIO?
The P/E ratio data is currently unavailable.
What is the dividend yield for JBIO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -49.11%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.13.
Analyst Recommendation Trends
Wall Street analyst consensus for JBIO over the last few months:
Latest JBIO News
Wedbush Reiterates Outperform on Jade Biosciences, Maintains $47 Price Target
Wedbush analyst Laura Chico reiterates Jade Biosciences (NASDAQ:JBIO) with a Outperform and maintains $47 price target.
HC Wainwright & Co. Reiterates Buy on Jade Biosciences, Maintains $55 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Jade Biosciences (NASDAQ:JBIO) with a Buy and maintains $55 price target.
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis - Slideshow
2026-09-30. The following slide deck was published by Jade Biosciences, Inc.
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript
Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis September 30, 2026 8:30 AM EDTCompany...
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
JADE301 is designed to build on a clinically validated IFN-β mechanism with a differentiated profile designed for infrequent subcutaneous dosingJADE301 demonstrated high-affinity, selective IFN-β binding and greater functional potency than a dazukibart comparator in disease-relevant human cellsFollowing subcutaneous administration in non-human primates, JADE301 was effectively half-life extended with an approximately 25-day half-life and predictable distribution into muscleJADE301 was well toler
Jade Biosciences, Inc. (JBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Jade Biosciences, Inc. (JBIO) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 9:20 AM EDTCompany ParticipantsTom Frohlich - President,...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-25 | Eisner Mark | +47,675 | - | - |
| 2026-06-09 | CAIN CHRISTOPHER W. | +34,843 | - | - |
| 2026-06-09 | Klein Lawrence Otto | +34,843 | - | - |
| 2026-06-09 | Lavelle Erin | +34,843 | - | - |
| 2026-06-09 | Harwin Peter Evan | +34,843 | - | - |
| 2026-06-09 | DOBMEIER ERIC | +34,843 | - | - |
| 2026-02-12 | Balta Elizabeth | +168,750 | - | - |
| 2026-02-12 | Balta Elizabeth | +28,125 | - | - |
| 2026-02-12 | Frohlich Tom | +472,500 | - | - |
| 2026-02-12 | Frohlich Tom | +78,750 | - | - |
| 2026-02-12 | King Andrew James | +247,500 | - | - |
| 2026-02-12 | King Andrew James | +41,250 | - | - |
| 2026-02-12 | Dahms Bradford D. | +226,875 | - | - |
| 2026-02-12 | Dahms Bradford D. | +37,813 | - | - |
| 2025-10-06 | Harwin Peter Evan | +855,047 | $9.1399 | $7,815,044 |
| 2025-10-06 | Harwin Peter Evan | +1,333,126 | $9.14 | $12,184,772 |